Mesoblast Limited (ASX:MSB)
Australia flag Australia · Delayed Price · Currency is AUD
1.810
-0.075 (-3.98%)
Nov 17, 2026, 11:22 AM AEDT
← View all transcripts

AGM 2026

Nov 9, 2026

Summary

FY 2026 revenue reached $115 million, with $110 million in gross profit on sales. Priorities include RYONCIL expansion, 2027 chronic back pain trial results, and advancing heart failure programs toward filing.

Silviu Itescu
Chief Executive and Managing Director, Mesoblast

Thanks very much, Phil. We'll go to the first slide, please. Thank you. Our corporate vision: To be the world's leading and most innovative cellular therapies company, to use our proprietary technologies to develop cellular medicines that are life-saving and that transform lives, to be an organization that displays efficiency and attracts highly motivated professionals working towards a common goal, and to deliver appropriate returns for you, our shareholders. Next slide, please. FY 2026 was a great year. There were a number of highlights. Let me just touch on a few of them. Importantly, we had net revenues of $115 million for the year, with gross profits on sales of $110 million.

The major milestones were that we completed 350 patients treated in the phase III trial, the pivotal phase III trial for the blockbuster product in chronic low back pain, a major update, and we look forward to the outcome in around mid-year to the third quarter of this calendar year, 2027. Alignment with the FDA was achieved on filing for approval in our end-stage heart failure indication. We've initiated a registration trial for label extension of RYONCIL in adults with adult acute graft-versus-host disease. It's currently enrolling patients, and we're targeting 40 sites across the U.S. We achieved approval from the FDA to begin a pivotal trial in Duchenne's, a label extension of RYONCIL in a pediatric inflammatory disease with major unmet needs. We entered into a $125 million, five-year, non-dilutive credit line facility, which consolidated and retired two higher-cost facilities. Next slide, please.

Now, we have a market leadership position that we call our moat. We have a global IP portfolio of more than 1,000 patents that provide protection, long-term protection against competitors through at least 2044. We continue to develop our IP portfolio, and this underpins a scalable commercial business model for our products. We have a first-mover advantage. We have the only FDA-approved mesenchymal stromal cell therapy called RYONCIL. There are no others in the U.S. We're leveraging FDA guidance so that we can obtain further label extensions for this approved product in various indications associated with severe inflammation. We've completed a large U.S. based randomized clinical trial, multiple clinical trials across multiple indications so that we can sit behind our evidence of efficacy and demonstrate how we are years ahead of everybody else in terms of accumulating clinical data.

We're the leader in manufacturing with IP protection, with significant know-how, significant advantages around FDA alignment, scale-up capacity, and ability to leverage across all of our products. We also have next-generation technology, which allows us to pinpoint our products to target new indications with even greater efficacy, again, in inflammatory conditions. As important as everything else, we've got an executive leadership team with proven capability to bring our cutting-edge cell therapy products to market. Next slide, please. Our commercialization of the allogeneic cellular therapies is based on three pillars. The first is, as I've mentioned, we have the only FDA-approved mesenchymal stromal cell product with a successful first-year launch. Highly profitable product if this was on a standalone basis, but importantly, this has the ability to be leveraged across multiple pediatric and adult indications where the underlying mechanism is to turn off severe life-threatening inflammation.

We've been able to build, in a parallel timeframe, a commercial infrastructure to support product launches both for RYONCIL, but importantly, it's going to be very important for the next generation of products, which are going to be even more valuable. We've demonstrated through our sales and market access team that we've been able to onboard more than 50 sites across the U.S. for this first product. More than 98% of lives are covered by commercial insurance, and equally as important, we've got government insurance. We've got Medicaid with a J-code that was obtained in record time, so that all states across the U.S. are mandated to cover this product at full price. The third pillar is, of course, our growth engine, rexlemestrocel-L. This is the growth engine for our blockbuster opportunities.

It provides late-stage opportunities through phase III and beyond to disrupt massive pain and cardiovascular markets with substantial unmet medical needs. We'll talk more about the opportunity in chronic low back pain and in heart failure, particularly in those patients with pulmonary hypertension, a major unmet need with severe mortality. Next slide, please. The expanding opportunities of rexlemestrocel-L in these major indications in blockbuster areas like pain and cardiovascular disease mandates that we need to expand our operational management. As such, we will initiate a search for a U.S.-based Chief Operating Officer to prepare for our commercial manufacturing scale-up and potential commercial launch activities of rexlemestrocel-L. Dr. Greg George will be interim COO, with extensive operational experience, having founded and managed the largest privately owned ambulatory surgical center company in the United States, SurgCenter Development, with more than 250 centers across more than 30 states.

Dr. Eric Rose will focus his efforts as Chief Medical Officer on advancing the transformational opportunities for rexlemestrocel-L in our cardiopulmonary franchise and will step away from board activities. As you heard from Phil, the board of directors will continue to globally search for additional directors with biopharma, manufacturing, and commercial expertise. Phil, the board of directors will continue to globally search for additional directors with biopharma, manufacturing, and commercial expertise. The first of these, Jon Voigtman, who's subject to approval by shareholders, will join the board after today's meeting. Bill Burns and Phil Krause will retire from the board. Next slide, please. This slide is a snapshot of our pipeline. As you can see in blue, our first-generation product, remestemcel-L or RYONCIL, already commercialized, being sold with a substantial total addressable market.

Its pipeline extension is in adults beyond pediatric, and of course, we're leveraging the mechanism in other areas of inflammation in children, such as Duchenne's. In green, you see our second-generation product, rexlemestrocel-L, and it's being developed for a variety of cardiovascular applications and for inflammatory back pain, with much larger total addressable markets. Next slide, please. RYONCIL, our lead product approved and in market for steroid-refractory acute graft-versus-host disease in children. Next slide, please. Beyond the pediatric opportunity, we see that the adult opportunity in severe grade 3/4 GVHD is the opportunity for next growth of this product, and as such, we've initiated a randomized controlled trial of up to 180 patients together with the Bone Marrow Transplant Clinical Trials Network across the U.S., an NIH-funded body, aiming to position RYONCIL as part of the second-line therapy in combination with ruxolitinib.

There are about 2,000 patients annually in the U.S. with steroid-refractory GVHD adults, of whom about half have got grade 3/4 disease. The registration trial is 180 patients randomized one-to-one to ruxolitinib alone versus ruxolitinib plus RYONCIL. The primary endpoint is day 28 overall response, with a secondary endpoint of day 180 overall survival. We are targeting up to about 40 U.S. centers, which represent about 50% of all the allo transplants performed across the U.S. The expected duration of this trial is 18 to 24 months, with a potential interim analysis for early success at the end of next year. More about this over the coming months. Next slide, please. Now, let's talk a little bit about our blockbuster opportunities for rexlemestrocel. Firstly, for the chronic low back pain due to degenerative disc disease opportunity. Next slide, please.

We have already completed one phase III trial, which demonstrated significant pain reduction through 12 months and duration for as long as 36 months. On the back of that trial, we have agreed with the FDA to complete a confirmatory randomized controlled trial. 350 patients in this trial have already been enrolled and fully treated. This trial will read out around the middle of next year, with a primary endpoint being 12 months pain reduction and a secondary endpoint of improvement in function. If we achieve the primary endpoint, the FDA has agreed that we may file for product approval. In parallel to this trial reading out next year, we, of course, will continue to scale up manufacturing so that in parallel with having clinical outcomes, we are in a position to commence a filing for approval with a commercially manufactured product. Potentially, approval would be in calendar year 2028.

Just to show you schematically what we do with this product, you can see on the left-hand side here, a normal disc in blue is quiet and it acts like a cushion. When you have significant inflammation of the disc, denoted here in red, this is the basis of severe inflammation, not responsive to various drugs and various traditional agents. We inject our cells right in the middle of this disc with a very specialized little cannula, and one injection of our cells for as low as six million of our cells, we expect will result in substantial and durable long-term improvement and improvement in function. Next slide, please. Now, the patient treatment journey for these patients is very clear. After conservative treatments, which we talk about non-steroidal anti-inflammatory drugs and other conservative approaches, the only option for these patients is opioids.

We all know the problem with opioids, the opioid epidemic, the large number of patients who die as a result of accidental overdosing, and they really don't work very well. Once you are through opioids, the only thing that is available is surgical intervention of one form or another, including device implantation and ultimately spinal fusion. So, beyond conservative treatments, there is really nothing else other than what we offer these patients with chronic severe pain. There are 7 million patients across the U.S. who fall into this category of disease. Next slide, please. Now, the physicians who see these patients, 90% of them are either primary care physicians or pain specialists in multidisciplinary clinics. So this is not a surgical problem. This is really a pain doctor problem.

These physicians know fully well how tough it is to treat these patients and how they have got very little to offer them.

We work with these physicians in terms of understanding their needs and they understanding the treatment potential of our drug. Next slide, please. When we go out and do special reviews and interface with the KOLs, the key opinion leaders, we've presented them with data, for example, from our previous randomized control trial. You can see that in those pain specialists who treat 90% of these patients, their comments are that 85% of these pain physicians, on the basis of having looked at our results from our first phase III trial, are very likely to recommend rexlemestrocel-L for the treatment of chronic low back pain based on the outcomes they've already seen. We're very confident that this is the physician target that will use our product as we move forward commercially. Next slide, please. Now let's move to the rexlemestrocel-L product for the cardiovascular indications.

Next slide. Our cardiopulmonary indications leverage a very shared common mechanism. Rexlemestrocel-L targets inflammation in the heart. By turning off inflammation, which is the driver of heart failure, and it's the driver of multiple complications in cardiovascular disease, it allows blood vessels to dilate. Those are the coronary arteries, the pulmonary arteries, and even the arteries in your gut.

You can start to see how a common mechanism like that underpins the results that we've achieved through multiple randomized control trials in patients with end-stage heart failure who are being kept alive with an artificial heart, an LVAD, in patients with traditional class II, III heart failure, which is a very large market opportunity, and more recently, in patients with what's called group two pulmonary hypertension, which is a major complication seen in about 40% of patients with heart failure, and actually, there are no drugs approved for this indication, which has a very high mortality. Fundamentally, what we're leveraging here is a shared mechanism where the cells directly injected into the heart turns off the severe inflammation that causes these problems. Next slide, please. Next slide.

In this regard, we recently met with the FDA to talk about our program in end-stage heart failure, patients being kept alive with an LVAD, where the primary outcome that we achieved was a reduction in life-threatening major bleeding in the gastrointestinal tract. The reason for that, as I've mentioned earlier, the inflammation causes abnormalities in the blood vessels, and these patients bleed. They have roughly a six or sevenfold increase in bleeding compared to normal patients, and we bring that right back to normal with a single injection into the myocardium. The message with the FDA was a very positive one, where the FDA aligned with us and agreed that we may go forward with a filing for approval. Of course, what we're doing in parallel to the clinical program is to complete our commercial manufacturing and the CMC piece that will go hand-in-hand with a filing for approval.

Next slide, please. Beyond this patient population and on approval of one indication, we think we can leverage such an approval into these other areas like pulmonary hypertension. This is an area that we haven't really talked about, but has recently become evident that is a major problem in heart failure patients for which there's nothing approved. Essentially, the dysfunctional left ventricle results in high pressure back in the lungs and failure of the right ventricle with a high mortality. Next slide, please. In our DREAM-HF population of 565 patients randomized control trial, when we look at those patients with high pulmonary artery pressure, which is the definition of pulmonary hypertension, in that group of patients, which accounts for about 40% of the total population, a single injection of rexlemestrocel significantly improved ventricular diastolic function and resulted in reduction in pulmonary hypertension.

The most important point here is that it resulted in a 53% reduction in mortality. This is unheard of in this disease, and it's the basis for moving forward in this area together with potential strategic alliances. Next slide, please. This is a big market, potentially 1.1 million patients in the U.S. alone, and there are no approved drug therapies for this indication, including drugs that are approved for parallel diseases like primary pulmonary hypertension do not work in this indication. We're very excited about these data. Next slide, please. Finally, my last slide. We have next-generation technologies as well, and we're excited about these. Next slide.

We talked a little during the course of the year at the R&D Day, where we brought in technology from the Mayo, which allows us to leverage technology that's in the market in CAR- T therapies, which have, with CAR- T, lots of safety issues. By applying those technologies to our cells, we have none of the safety issues, but what we really have is the ability to pinpoint target our cells, a greater effectiveness to the area of inflammation, which results in an even greater potency of these next-generation products compared to the ones we already have for diseases that, to date, continue to be refractory, like lupus nephritis, a big area of unmet need. Next slide, please. Next slide. In summary, we have three areas that are going to continue to drive value for the shareholders over the next year to two years.

On the left-hand side, of course, RYONCIL is all about growth of revenues. It's about expansion into new indications that we can leverage, and it's about extension into pediatric diseases and other areas in adults. Our blockbuster program for chronic low back pain has completed its pivotal randomized control trial, and we'll have a major readout, middle to third quarter of calendar year 2027. The trial completion will leverage our ability to move into filing for the FDA whilst we, at the same time, complete our commercial manufacturing for the product. The blockbuster program in heart failure, we will complete the filing. Again, the manufacturing will be leveraged across both back and heart. We will then be able to also work on extending the label into new indications like pulmonary hypertension, which will allow us to pursue cardiopulmonary strategic alliances.

I think on that note, which I think gives you a sense of the excitement that is about to come, I would like to open it up for any questions, please. Thank you.